SCHEMBL166372

SCHEMBL166372

COC(=O)c1cc(C)c(Br)cc1OC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
KDM4E B2RXH2 4/20 0.41
ACHE P22303 1/20 0.41
CFD P00746 2/20 0.39
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
TNFSF11 O14788 1/20 0.38
HSD17B10 Q99714 2/20 0.37
HTT P42858 2/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
PKM P14618 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NOTUM Q6P988 1/20 0.36
SOS1 Q07889 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167967 0.94 POLB (0.51) POLBKDM4EACHECFDMAPT
SCHEMBL22134879 0.85 GAA (0.50) POLBKDM4EMAPTLCKFYN
SCHEMBL23094468 0.85 KDM4E (0.45) POLBKDM4EACHECFDMAPT
Ammonia Solution, Strong SCHEMBL22116619 0.83 GAA (0.49) POLBKDM4EMAPTLCKFYN
SCHEMBL5154161 0.81 SOS1 (0.45) KDM4EACHEMAPTHSD17B10GAA
SCHEMBL167752 0.80 KDM4E (0.39) POLBKDM4ECFDMAPTMAPK1
SCHEMBL18420521 0.79 NOTUM (0.45) KDM4EACHEMAPTHSD17B10GAA
SCHEMBL31385726 0.79 NOTUM (0.45) KDM4EACHEMAPTHSD17B10GAA
SCHEMBL29266104 0.78 POLB (0.55) POLBKDM4EACHECFDMAPT
SCHEMBL166802 0.78 GAA (0.50) POLBKDM4EMAPTLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 POLB 1496/4885KDM4E 1447/4885ACHE 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.